Literature DB >> 8704186

Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.

R W Humphrey1, T R O'Brien, F M Newcomb, H Nishihara, K M Wyvill, G A Ramos, M W Saville, J J Goedert, S E Straus, R Yarchoan.   

Abstract

Herpesvirus-like DNA sequences (KSHV/HHV-8) have recently been described in AIDS-associated Kaposi's sarcoma (KS) lesions. Many questions remain regarding the role of this virus in KS and the therapeutic implications of this finding. In the current study, KSHV/HHV-8 DNA was detected in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus (HIV)-infected patients with KS (34/98) more often than in HIV-infected individuals without KS (12/64, P = .03). The detection of KSHV/HHV-8 DNA did not correlate with the CD4 lymphocyte count. Five patients demonstrated KSHV/HHV-8 DNA in their PBMCs during administration of intravenous foscarnet and/or ganciclovir. The continued detection of KSHV/HHV-8 DNA in the PBMCs of patients receiving these anti-herpesvirus drugs has potential implications regarding the virus-cell relationship of KSHV/HHV-8, as well as for the value of these drugs in treating or preventing KS, but additional studies are needed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704186

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents.

Authors:  J P Zoeteweij; S T Eyes; J M Orenstein; T Kawamura; L Wu; B Chandran; B Forghani; A Blauvelt
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir.

Authors:  E A Gustafson; R F Schinazi; J D Fingeroth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

4.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

5.  Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection.

Authors:  T J Spira; L Lam; S C Dollard; Y X Meng; C P Pau; J B Black; D Burns; B Cooper; M Hamid; J Huong; K Kite-Powell; P E Pellett
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

6.  Human Herpesvirus 8 Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 7.  A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.

Authors:  G Nasti; D Errante; S Santarossa; E Vaccher; U Tirelli
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

Review 8.  Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases.

Authors:  Dharam V Ablashi; Louise G Chatlynne; James E Whitman; Ethel Cesarman
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

9.  Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood.

Authors:  Lan Lin; Jeannette Y Lee; Lawrence D Kaplan; Bruce J Dezube; Ariela Noy; Susan E Krown; Alexandra M Levine; Yanxing Yu; Gary S Hayward; Richard F Ambinder
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

10.  Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.

Authors:  G Boivin; A Gaudreau; E Toma; R Lalonde; J P Routy; G Murray; J Handfield; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.